Last updated: 11/07/2018 14:56:30
Study In Patients With Insulin Resistance
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A single-centre, randomised, double-blind, placebo controlled, two 12 week period, cross-over phase III study to investigate the effect of rosiglitazone 4mg bd on the vasodilator response to hyperinsulinaemia in obese insulin resistant subjects.
Trial description: Fluid management study in patients with insulin resistance.
Primary purpose:
Treatment
Trial design:
Crossover Assignment
Masking:
Not applicable
Allocation:
Randomized
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Enrollment:
18
Primary completion date:
2003-31-08
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Insulin resistance
Product
rosiglitazone
Collaborators
Not applicable
Study date(s)
October 2002 to August 2003
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
30 - 65 years
Accepts healthy volunteers
No
- BMI 27-36 kg/m2 inclusive and at least two additional features of the metabolic
- syndrome or a first degree relative with
- Subjects with type 2 diabetes mellitus defined as an HbA1c level >6.5% or a fasting
- plasma glucose of > 7.0 mmol/L. If fasting plasma glucose is between 6.1 and 7.0
Inclusion and exclusion criteria
Inclusion criteria:
- BMI 27-36 kg/m2 inclusive and at least two additional features of the metabolic syndrome or a first degree relative with a history of type 2 diabetes mellitus. BMI = Weight/height², (where weight is in kg, height in m).
- Male or female aged 30 to 65 years, inclusive, at screening.
- Female subjects must be post-menopausal (i.e. >6 months without menstrual period), surgically sterile, or using effective contraceptive measures (oral contraceptives, Norplant Depo-Provera) or intra-uterine devices (IUD) (a diaphragm with spermicide or a condom with spermicide). Women of childbearing potential must use effective contraceptive measures for at least 1 month prior to visit 1, and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study treatment.
- Willing and able to provide a signed and dated written informed consent.
Exclusion criteria:
- Subjects with type 2 diabetes mellitus defined as an HbA1c level >6.5% or a fasting plasma glucose of > 7.0 mmol/L. If fasting plasma glucose is between 6.1 and 7.0 mmol/L then a 75 g oral glucose test will be performed to exclude diabetes mellitus.
- Subjects who have initiated lipid lowering therapy within the last 6 months and subjects who have increased the dose of these therapies within the last 3 months prior to study start.
- Subjects who are taking Non Steroidal Anti-inflammatory Drugs, fibrates, anticoagulants or cardiovascular medications (β-blockers, nitrates, calcium antagonists, ACE inhibitors, angiotensin II antagonists, alpha blockers, diuretics, centrally acting anti-hypertensives, directly acting antihypertensives e.g., diazoxide, digoxin, anti-arrhythmics) and are unable to stop these medications for the duration of the study.
- Exposure to a thiazolidinedione (TZD) or other PPAR-γ agonist (e.g. rosiglitazone, troglitazone, pioglitazone, G1262570) within the last 4 months or participation in a clinical study involving a TZD or PPAR-γ agonist.
- Subjects who have required the use of any anti-diabetic medication at any time.
- Use of any investigational drug within 30 days preceding the first dose of medication at the start of the study.
- Subjects with a documented history of significant hypersensitivity (e.g. difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to thiazolidinediones or PPAR-γ agonists.
- Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg or receiving antihypertensive therapy.
- Subjects with unstable or severe angina (requiring continual therapy) or congestive heart failure.
- Presence of clinically significant hepatic disease.
- Clinically significant anaemia.
- Subjects with creatinine clearance <40 mL/min.
- Women who are lactating, pregnant or planning to become pregnant during the course of the study.
- Alcohol or drug abuse within the last 6 months.
Trial location(s)
Location
GSK Clinical Trials Call Center
Nijmegen, N/A, Netherlands, 6525EZ
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
2003-31-08
Actual study completion date
2003-31-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website